Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer

類似資料

• Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel
  著者:: Kantelhardt, Eva J, 等
  出版事項: (2011)
• The Role of uPA and uPA Inhibitors in Breast Cancer
  著者:: Bevan, Paul, 等
  出版事項: (2008)
• uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies
  著者:: Duffy, Michael J, 等
  出版事項: (2014)
• Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer
  著者:: Goldstein, Lori J.
  出版事項: (2008)
• Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer
  著者:: Bruno Märkl, 等
  出版事項: (2019-07-01)